<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354678</url>
  </required_header>
  <id_info>
    <org_study_id>IMPI-1</org_study_id>
    <nct_id>NCT01354678</nct_id>
  </id_info>
  <brief_title>Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia</brief_title>
  <acronym>IMPI</acronym>
  <official_title>Phase 1 Study to Evaluate the Efficacy and Safety of Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised placebo-controlled study of efficiency and safety of bone marrow mononuclear cells
      transplantation by intramyocardial multiple precision injection in ischemic heart failure
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increase of prevalence of heart failure in human population requires to develop new and
      effective methods of treatment. One of them is stem cells transplantation into a myocardial
      tissue, which cause the improvement of contractility, myocardial remodelling after myocardial
      infarction (MI), dilated cardiomyopathy, etc. Use of autologous stem cells does not require
      of immunosuppressive therapy and does not correlate with some ethical problems. Clinical
      application of mesenchymal stem cells always requires a step of culturing, which is
      associated with increased risk of contamination Therefore haemopoietic stem cells,
      endothelial progenitor cells or mononuclear bone marrow cells are often used to be transplant
      for treatment of heart failure (HF) patients.Using NOGA XP Cardiac Navigation System improves
      specificity of transplantations, that is decisive.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global left ventricular ejection fraction and regional wall motion score index</measure>
    <time_frame>6 and12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the major adverse cardiac events</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>group of bone marrow cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group of sham therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>NOGA XP Cardiac Navigation System</intervention_name>
    <description>Intramyocardial multiple precision injection of bone marrow mononuclear cells</description>
    <arm_group_label>group of bone marrow cell therapy</arm_group_label>
    <other_name>Cordis Corporation's Biologics Delivery Systems</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>NOGA XP Cardiac Navigation System</intervention_name>
    <description>Intramyocardial multiple precision injection with placebo</description>
    <arm_group_label>group of sham therapy</arm_group_label>
    <other_name>Cordis Corporation's Biologics Delivery Systems</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with coronary artery disease (CAD) and HF II-III NYHA class

          -  MI more than 6 months before the study

          -  LVEF less than 35%

          -  absence of indication to coronary revascularization

          -  optimal pharmacological therapy no less than 8 weeks

          -  heart transplantation is contraindicated

          -  patients with implantable cardioverter-defibrillator (ICD) or cardiac
             resynchronization therapy defibrillator (CRT-D)

          -  patients giving informed consent

        Exclusion Criteria:

          -  acute coronary syndrome

          -  coronary revascularization less than 6 months

          -  patients requiring surgical correction of post-MI aneurism

          -  LV wall thickness less than 5 mm in site of possible injection

          -  patients with CRT implanted within 3 month before cells injection

          -  clinically significant associated diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene V Shlyakhto, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Almazov Federal Heart, Blood and Endocrinology Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almazov Federal Heart, Blood and Endocrinology Centre</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>bone marrow mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

